

INVESTOR PRESENTATION

Improving Vascular Health with AI-driven Early Disease Detection & Surgical Precision

230 Million Patients. FDA-Cleared Triage AI. One Company.

CBOE: GDAI





Terms of Use

This investor presentation is being provided for the sole purpose of providing the recipients with background information about GuideAI Health Corp. (the "Company"). The Company has made reasonable efforts to ensure that the information contained in this presentation is accurate as of the date hereof, however, there may be inadvertent or unintentional errors. No representation, warranty or guarantee, express or implied, is made as to the fairness, accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. The views and information provided herein are based on a number of estimates and assumptions that are subject to significant exploration, business, economic, regulatory and competitive uncertainties. See "Forward-Looking Statements" below. The Company is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation. Unless otherwise indicated or the context otherwise requires, all references in this presentation to the "Company", "GuideAI", "we", "our", "us", or similar terms refers to GuideAI Health Corp., together with its subsidiaries.

This presentation provides information in summary form only, is not intended to be complete and does not constitute an offer to sell or the solicitation of an offer to buy any security. It is not intended to be relied upon as advice to investors or potential investors and does not constitute a personal recommendation or take into account the investment objectives, financial situation or needs of any particular investor. The Company is not acting as agent or advisor and encourages the use of independent consultants, as necessary, prior to entering into transactions. Any unauthorized use, disclosure, distribution or copying of this document by anyone other than the intended recipient is strictly prohibited.

Forward-Looking Statements

This presentation contains forward-looking statements and forward-looking information (collectively, "forward looking statements") within the meaning of applicable Canadian securities legislation. Forward looking statements are often identified by words such as anticipate, believe, expect, intend, plan, estimate, potential, may, will, should, continue, target, or similar expressions. Forward looking statements in this presentation may include, but are not limited to, statements regarding the Company's business strategy, technology development, regulatory pathways, commercialization plans, market opportunity, partnerships, anticipated growth, future financial performance, and the Company's ability to successfully develop and deploy its artificial intelligence healthcare platform.

Forward-looking statements are based on management's current expectations, assumptions, and beliefs regarding future events and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results or outcomes to differ materially from those expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to, risks related to regulatory approvals, technological development, commercialization and market adoption, competition, access to capital, partnerships, data availability, intellectual property protection, and general economic and market conditions. These risks and uncertainties and other factors are discussed under the heading "Risk Factors", in the Final Prospectus of GuideAI dated June 12, 2026, which is posted on SEDAR+ at sedarplus.ca.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements are made as of the date of this presentation and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.

The information contained in this presentation has been prepared to assist prospective investors in evaluating the Company but does not purport to be complete. Certain information contained herein may be derived from third party sources believed to be reliable; however, the Company has not independently verified such information and makes no representation or warranty as to its accuracy or completeness. Recipients of this presentation should conduct their own independent investigation and analysis of the Company and consult their own professional advisors prior to making any investment decision.

Neither the Company nor any of its directors, officers, employees, advisors, or representatives accepts any liability whatsoever for any loss arising directly or indirectly from the use of, or reliance upon, the information contained in this presentation.



Investment Highlights



\$200B+ Peripheral Arterial Disease (PAD) Problem¹

Peripheral Arterial Disease (PAD) is widely underdiagnosed and contributes to more than \$200B in annual healthcare costs in the United States, highlighting a significant opportunity for earlier detection through AI-driven screening.



vRad Data Partnership

Access to one of the world's largest medical imaging datasets through GuideAI's partnership with vRad, strengthening AI model training, validation, and the accuracy of vascular disease detection.



First AI Platform for PAD Detection

AI powered early detection of Peripheral Artery Disease (PAD) from routine CT scans.



A Proven Blueprint

HeartFlow has shown that AI applied to vascular imaging can secure Category I reimbursement and generate hundreds of millions in annual revenue — validating the path GuideAI Health is now following.



200+ Global Hospital LOIs

Led by experienced radiologists, AI engineers, and healthcare operators.



Seasoned Leadership Team

Led by experienced radiologists, AI engineers, and healthcare operators.



FDA Regulatory Pathway

Designed for regulatory clearance and seamless integration into hospital workflows.



Hospital Revenue Expansion

GuideAI's platform enables hospitals to detect previously missed vascular disease cases, improving patient outcomes while generating new diagnostic revenue opportunities.



FDA 510(k) Clearance

GuideAI received FDA 510(k) clearance for VascularAssist Occlusion Triage (VAOT), an AI device that flags suspected vascular occlusion for prioritized radiologist review, achieving up to 95% patient level sensitivity in clinical performance testing.

Sources: ¹<https://www.thesagegroup.us/press-releases/according-to-the-sage-group-the-annual-economic-burden-of-critical-limb-ischemia-cli-exceeds-200-billion/>



A Proven Blueprint. An Unaddressed Market.

HEARTFLOW INC.

**\$176M Revenue¹ (FY 2025)
2025)**

- ✓ Built on AI + Coronary Imaging
- ✓ 200M patient population²
- ✓ Market Cap: ~\$3.02B³

GUIDEAI HEALTH

Early-Stage Opportunity

- ✓ Targeting Multiple Vascular Diseases (Starting with Peripheral Arterial Disease)
- ✓ Multiple Advanced AI Models, Full Vascular Analysis
- ✓ Today: Pre-Revenue / FDA Approved for VAOT

HeartFlow validated the potential of AI-enabled imaging and clinical decision support in coronary artery disease. GuideAI is applying a similar approach to peripheral arterial disease, a large and under-served patient population with limited dedicated AI-focused solutions today.

¹<https://www.theglobeandmail.com/investing/markets/markets-news/motley/2633013/heartflow-vs-novocure-which-emerging-healthcare-stock-is-a-better-buy-in-2026/>

²<https://ir.heartflow.com/news-releases/news-release-details/heartflow-reports-first-quarter-2026-financial-results-and>

³<https://ca.finance.yahoo.com/quote/HTFL/>



At a Glance

	GuideAI Health VascularAssist™ · PAD · Early-detection AI	HeartFlow HeartFlow One · CAD · AI cardiac imaging
Focus	Peripheral arterial disease — arteries of the limbs and extremities outside the heart	Coronary artery disease — the heart's blood supply and flow dynamics
Core Product	AI image analysis applied to existing scans; structured PAD-detection reports for radiologists	3D coronary model from CCTA; FFR-CT, plaque characterization and roadmap analysis
Company Stage	Early commercial; seed-funded, clinical pilots active, academic partnerships in place	Public (Nasdaq: HTFL); \$176M revenue FY2025, 1,800+ institutions globally
Reimbursement	Regulatory pathway underway; reimbursement strategy in development	Category I CPT code secured for FFR-CT; ~99.5% of US lives covered ⁴
Clinical Evidence	Active hospital pilots; validation partnerships with leading academic medical centers	600+ peer-reviewed publications; multiple completed RCTs including PRECISE and ADVANCE
Disease Population	~230M people globally with PAD; majority undiagnosed until late-stage ¹	~200M people globally with coronary artery disease; leading cause of death worldwide ²

¹WHO / ISCVS global PAD prevalence

²[https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))

THE PROBLEM

Peripheral Arterial Disease: 230 Million Patients, Routinely Missed

230M¹

People with PAD globally

63%+²

of significant cardiovascular findings go
unreported on routine CT


1M+³

Amputations annually — can be preventable

¹<https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065470>

²[https://www.ejradiology.com/article/S0720-048X\(24\)00549-7/fulltext](https://www.ejradiology.com/article/S0720-048X(24)00549-7/fulltext)


³<https://promedea.com/limb-loss-statistics/>



PAD progresses silently. By the time it's detected, patients face amputations, heart attacks, and strokes. The markers are in the imaging data — they're just not being found.



50 CT Scans Per Day. 5 Images Per Second. Disease Gets Missed.



THE RADIOLOGIST REALITY

- A single CT scan = hundreds of individual images
- Average workload: 50 CT scans per day
- That's 5 images processed every second
- Up to 88% of radiologists report burnout globally¹
- PAD markers are subtle, spread across complex anatomy

Significant arterial narrowing (50%+ stenosis) is often missed, under-reported due to poorly characterized by Radiologists

This isn't a skills problem. It's a volume and complexity problem — exactly the kind of problem AI was built to solve.



Behind Every Missed Scan Is a Patient

WITHOUT EARLY DETECTION

- ✗ Silent disease progression
- ✗ Critical limb ischemia
- ✗ Amputation
- ✗ \$25,000+ in long-term care costs per patient¹

WITH GUIDEAI EARLY DETECTION

- ✓ AI can flag early vascular markers
- ✓ Physicians better equipped to intervene early
- ✓ Potential to reduce amputations
- ✓ Potential for patients continues normal life

About **75% of PAD-related healthcare** costs come from hospitalizations¹ — the late-stage events earlier detection is meant to avoid.



Four Forces That Make This the Right Moment



Diabetes Epidemic

IDF projects 853M adults with diabetes by 2050 — PAD's primary risk factor. Every new diagnosis is a patient whose vascular health needs monitoring¹.



AI Imaging Market

\$2.2B in 2026, forecast \$17.8B by 2033 at 34.8% Compound Annual Growth Rate (CAGR). Deep-learning platforms with clinical validation are the primary growth driver².



Value-Based Care

Hospitals and payers are increasingly rewarded for outcomes, not volume. Early detection is a financial imperative, not just a clinical good.



FDA Pathway Proven

More than 500 AI-enabled medical devices have received regulatory clearance, reflecting a well-established pathway for clinical AI adoption³.

¹Diabetes: <https://diabetesatlas.org/>

²AI Imaging Market: <https://www.coherentmarketinsights.com/industry-reports/ai-in-medical-imaging-market>

³<https://ai.nejm.org/doi/full/10.1056/Aloa2300030>



VascularAssist— Finding What Others Miss



No New Hardware

Designed to integrate with existing CT imaging infrastructure, with the goal of minimizing disruption to clinical workflows.



AI-Powered Detection

Deep learning trained on data from 2,100+ hospitals. Mimics expert radiologist diagnostic approach.



Actionable Output

Structured, standardized reports. Clear findings that can change clinical decisions immediately.


HeartFlow demonstrated the commercial potential of AI-powered analysis. GuideAI is applying a similar approach to the peripheral vascular system.



HeartFlow Built \$176M/Year. GuideAI Is at Day Zero of the Same Curve.

The roadmap exists. The question is who applies it next. GuideAI has the team, the data, and the technology to follow it.

HeartFlow Revenue Trajectory



→ GuideAI Health — FDA Clearance of VAOT Approved

\$176M¹

HeartFlow FY2025 Revenue

40%

Year-over-year growth

\$936M²

Total capital raised

~\$2.5B³

Current market cap

¹<https://www.theglobeandmail.com/investing/markets/markets-news/motley/2633013/heartflow-vs-novocure-which-emerging-healthcare-stock-is-a-better-buy-in-2026/>

²https://tracxn.com/d/companies/heartflow/_x48xFTvIU63PhPT5IcQ47yBYTcl9I9Zn5IV07HGzUI/funding-and-investors#funding-rounds

³<https://ca.finance.yahoo.com/quote/HTFL/>



The Valuation Gap Is the Opportunity

230M¹

Patients with Peripheral Arterial Disease

\$6B²

Addressable medical imaging AI market (28% CAGR)

\$20B³

Total AI in medical imaging by 2029

\$233B+⁴

Annual US healthcare cost burden of PAD

HeartFlow targets 200M coronary patients, valued at ~\$3.02B. GuideAI targets 230M PAD patients with no equivalent AI competitor. The comparable is direct. The gap is the opportunity.⁵

¹<https://www.heart.org/en/health-topics/peripheral-artery-disease>

²<https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-medical-imaging-market>

³<https://www.precedenceresearch.com/ai-in-medical-imaging-market>

⁴<https://www.scai.org/government-relations/current-campaigns/peripheral-artery-disease>

⁵[https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(19\)30255-4/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30255-4/fulltext)

<https://ir.heartflow.com/news-releases/news-release-details/heartflow-inc-announces-closing-upsize-initial-public-offering>



Every Competitor Is in a Different Anatomy

Company	Focus Area	PAD Coverage
Viz.ai	Stroke / Brain	None
Aidoc	Acute radiology triage	None
Cleerly	Coronary arteries	None
HeartFlow	Coronary arteries	None
GuideAI Health	PERIPHERAL VASCULAR	FIRST MOVER

Rather than competing in an established category, GuideAI is helping create a new one



Recurring SaaS Revenue That Compounds With Each Disease Area



A predictable, high-margin SaaS model. Revenue grows as the platform expands — without proportional cost increases.



Milestone-Gated Revenue Trajectory

Radiology Group			Hospitals		Total	
Year	Total	\$ ' mm	Total	\$ ' mm	Total	\$ ' mm
2026	3	\$0.5	-	-	3	\$0.5
2027	5	\$0.8	10	3.0	15	\$3.8
2028	25	\$3.8	75	30.0	100	\$33.8
2029	50	\$7.5	250	125.0	300	\$132.5
2030	100	\$15.0	500	375.0	600	\$390.0

Projections based on management estimates. Forward-looking statements subject to risks.



200+ Hospital LOIs. World-Class Data. **Named Partners.**



vRad Partnership

Exclusive access to 1 billion+ medical images from 2,100+ hospitals. Largest training dataset in peripheral vascular AI.



Advocate Health LOI

69 hospitals. 6M patients served annually. Feasibility assessment underway for clinical integration.



Academic Medical Centres

Clinical validation studies underway at top-tier academic institutions.

200+ global hospital LOIs FDA approved represents a ready commercial pipeline.



Four Events That Will Move This Story

1	FDA Approved VAOT — 510k Clearance	Commercial launch trigger	Obtained
2	First Signed Hospital Contract	First revenue visibility	Post-FDA
3	CarotidAssist™ FDA Clearance	Second product, second revenue layer	Expected Q1 2027
4	International Pilot — India	Global expansion signal	Q1 2027



FDA Clears GuideAI's AI Software for Vascular Disease

1

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to GuideAI Health for its artificial intelligence software, VascularAssist Occlusion Triage (VAOT).

2

A 510(k) clearance permits the device to be marketed for its cleared use in the United States.

3

VAOT reviews routine CT scans of the lower legs and automatically flags signs of blocked or narrowed arteries.

4

It moves the most urgent cases to the front of the radiologist's queue so they are reviewed sooner. VAOT supports the radiologist and does not replace their diagnosis.

5

Peripheral Arterial Disease (PAD) is common, often underdiagnosed, and frequently caught late.

6

It is a leading contributor to limb-threatening loss of blood flow. Catching it earlier can speed up diagnosis and treatment.



How Well It Works and What It Means for GuideAI



How accurate it is (clinical performance testing)

- In testing, VAOT correctly flagged up to 95% of patients who had significant peripheral artery disease (95% on 2D analysis and 94% on 3D analysis).
- - “Significant” disease means at least one artery narrowed by 50% or more.



How it fits into hospitals

- VAOT runs inside the imaging systems hospitals already use, so radiologists do not need to change their tools or workflow to adopt it.



What it means for GuideAI

- This is a defining regulatory milestone that allows GuideAI to bring VAOT to hospitals and radiology groups in the United States.
- It is the foundation for GuideAI's broader goal of AI-driven vascular care.



Three Moats That Are Hard to Replicate



DATA

Exclusive access to 1B+ images from 2,100+ hospitals via vRad. More data = better AI = harder to displace.



CLINICAL ORIGIN

Built by interventional radiologists who saw the problem firsthand. Not retrofitted from general AI — purpose-built for PAD detection.




WORKFLOW INTEGRATION

Designed to plug into existing hospital radiology systems. Switching costs increase with every installed contract.



Clear Path to Market





Built by the Clinicians Who Saw What Was Being Missed

GuideAI was founded by interventional radiologists who spent careers reviewing imaging and repeatedly seeing early PAD go undetected. That clinical insight drives everything.



Raj Shah, MD MBA

Chief Executive Officer

Interventional Radiologist · Miami Cardiac & Vascular
of Connecticut



Luke Higgins, MD PhD

Chief Medical Officer & Chief Operating Officer

Interventional Radiologist · Stanford · Johns Hopkins ·
Brigham and Women's Hospital · MIT



Amin Katouzian, PhD

Chief Technology Officer

IBM Watson Health · 20+ patents · Columbia PhD · PI-CAI
Grand Challenge winner



Kourosh Jafari-Khouzani, PhD

Lead Data Scientist

IBM Watson Health · iCAD

Advisors: James Benenati MD (Penumbra CMO) · Gail Marcus (Natera/Cigna) · Himanshu Choksi (Bain/Stanford)

Management: Paul More (CFO) · Tasheel Jeerh (President)



GuideAI Health

Thank you

230 Million Patients. FDA-Cleared Triage AI. One Company.

CBOE: GDAI

